1. An arc evaporation device comprising an anode, a target (14) acting as a cathode or connected thereto, a voltage source connected to the anode and the cathode for generating an arc or arc spot (18, 20) on the target or its free surface (16), and a magnet arrangement (66) underneath the target and comprising an inner and an outer ring coil (70, 72) for generating a magnetic field influencing an arc movement on the target surface,
wherein
at least one of the ring coils (70, 72) of the magnetic arrangement (66) is assigned an element (74, 76) of high relative magnetic permeability (r>>1) influencing the magnetic field of the ring coil in the area of the surface (16) of the target, where the element assigned to the inner ring coil (70) peripherally surrounds the inner ring coil and the element assigned to the outer ring coil (72) extends along that surface of the outer ring coil facing the inner ring coil.
2. Arc evaporation device according to claim 1,
wherein
the element (74, 76) runs all round or substantially all round concentrically to the inner ring coil (70) or the outer ring coil (72).
3. Arc evaporation device according to claim 1 or claim 2,
wherein
the element (74, 76) has a relative magnetic permeability r with r104, in particularr106.
4. Arc evaporation device according to at least one of the previous claims,
wherein
the element (74, 76) comprises a ferromagnetic material.
5. Arc evaporation device according to at least one of the previous claims,
wherein
the element (74, 76) comprises iron, steel or an alloy such as permalloy.
6. Arc evaporation device according to at least one of the previous claims,
wherein
the arc is movable on account of the magnetic field generated by the magnetic arrangement (66) substantially along specified paths on the target surface (16), avoiding splitting into main and secondary branches.
7. Arc evaporation device according to at least one of the previous claims,
wherein
at least the inner ring coil (70) is surroundd by the element of high relative magnetic permeability (r>>1).
8. Arc evaporation device according to at least one of the previous claims,
wherein
the magnetic fields generated by the ring coils (70, 72) and acting in the area of the target surface (16) on the arc spot (18, 20) can be influenced by the elements (74, 76) of high relative magnetic permeability assigned to the outer and inner ring coils (70, 72) such that the magnetic field generated by the inner ring coil can be moved towards the target centre and the magnetic field generated by the outer ring coil can be moved towards the target edge.
9. Arc evaporation device according to at least one of the previous claims
wherein
the longitudinal axis of the target (14) and the longitudinal axes of the ring coils (70. 72) run in a common plane extending vertically to the target surface (16).
10. An arc evaporation device comprising an anode, a target (14) acting as a cathode or connected thereto, a voltage source connected to the anode and the cathode for generating an arc or arc spot (18, 20) on the target or its free surface (16) and a magnet arrangement (66) underneath the target and comprising at least one ring coil (70, 72) for generating a magnetic field influencing an arc movement on the target surface,
wherein
the at least one ring coil (70, 72) of the magnetic arrangement (66) is peripherally surrounded by an element (74, 76) of high relative magnetic permeability (r>>1) influencing the magnetic field of the ring coil in the area of the surface (16) of the target and wherein the magnetic arrangement is adjustable at least in an x andor y direction running parallel to the target surface.
11. Arc evaporation device according to claim 10,
wherein
the magnetic arrangement (66) is adjustable vertical to the target surface (16) in the z direction.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical composition comprising (a) acyclovir and (b) a delivery agent of the formula
or a salt thereof, wherein:
Ar is phenyl or naphthyl;
Ar is optionally substituted with one or more of \u2014OH, halogen, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy or C1-C4 haloalkoxy;
R7 is C4-C20 alkyl, C4-C20 alkenyl, phenyl, naphthyl, (C1-C10 alkyl) phenyl, (C1-C10 alkenyl)phenyl, (C1-C10 alkyl) naphthyl, alkenyl)naphthyl, phenyl(C1-C10 alkyl), phenyl(C1-C 10 alkenyl), naphthyl (C1-C10 alkyl), or naphthyl (C1-C10 alkenyl);
R8 is hydrogen, C1 to C4 alkyl, C2 to C4 alkenyl, C1 to C4 alkoxy, or C1-C4 haloalkoxy;
R7 is optionally substituted with C1 to C4 alkyl, C2 to C4 alkenyl, C1 to C4 alkoxy, C1-C4 haloalkoxy, \u2014OH, \u2014SH, \u2014CO2R9, or any combination thereof;
R9 is hydrogen, C1 to C4 alkyl, or C2 to C4 alkenyl; and
R7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination.
2. A pharmaceutical composition comprising (a) acyclovir and (b) a delivery agent of the formula
or a salt thereof, wherein
R1, R2, R3, and R4 are independently H, \u2014OH, halogen, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, \u2014C(O)R8, \u2014NO2, \u2014NR9R10, or \u2014N+R9R10R11 (R12)\u2212;
R5 is H, \u2014OH, \u2014NO2, halogen, \u2014CF3, \u2014NR14R15, \u2014N+R14R15R16(R13)\u2212, amide, C1-C12 alkoxy, C1-C12 alkyl, C2-C12 alkenyl, carbamate, carbonate, urea, or \u2014C(O)R18;
R5 is optionally substituted with halogen, \u2014OH, \u2014SH, or \u2014COOH;
R5 is optionally interrupted by O, N, S, or \u2014C(O)\u2014;
R6 is a C1-C12 alkylene, C2-C12 alkenylene, or arylene;
R6 is optionally substituted with a C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, \u2014OH, \u2014SH, halogen, \u2014NH2, or \u2014CO2R8;
R6 is optionally interrupted by O or N;
R7 is a bond or arylene;
R7 is optionally substituted with \u2014OH, halogen, \u2014C(O)CH3, \u2014NR10R11, or \u2014N+R10R11R12(R13)\u2212;
each occurrence of R8 is independently H, C1-C4 alkyl, C2-C4 alkenyl, or \u2014NH2;
R9, R10, R11, and R12 are independently H or C1-C10 alkyl;
R13 is a halide, hydroxide, sulfate, tetrafluoroborate, or phosphate; and
R14, R15 and R16 are independently H, C1-C10 alkyl, C1-C10 alkyl substituted with \u2014COOH, C2-C12 alkenyl, C2-C12 alkenyl substituted with \u2014COOH, or \u2014C(O)R17;
R17 is \u2014OH, C1-C10 alkyl, or C2-C12 alkenyl; and
R18 is H, C1-C6 alkyl, \u2014OH, \u2014NR14R15, or N+R14R15R16(R13)\u2212.
3. A pharmaceutical composition comprising (a) acyclovir and (b) a delivery agent of the formula
or a salt thereof, wherein
R1, R2, R3, R4 and R5 are independently H, \u2014CN, \u2014OH, \u2014OCH3, or halogen, at least one of
R1, R2, R3, R4 and R5 being \u2014CN; and
R6 is a C1-C12 linear or branched alkylene, alkenylene, arylene, alkyl(arylene) or aryl(alkylene).
4. A pharmaceutical composition of claim 1, wherein the delivery agent is selected from the group consisting of Delivery agents is SNAC or SNAD or a pharmaceutically acceptable salt thereof.
5. The pharmaceutical composition of claim 1 wherein the delivery agent is N-(8-2-hydroxybenzoyl-amino)caprylic acid or a pharmaceutically acceptable salt thereof.
6. The pharmaceutical composition of claim 1 wherein the delivery agent is wherein the delivery agent is N-(10-2-hydroxybenzoyl-amino)decanoic acid or a pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition provides bioavailability (i.e., AUC) substantially equivalent to the acyclovir formulation marketed as Zovirax\xae under U.S. FDA NDA No. 18828, 19909, or 20089 when:
(1) 200, 400, or 800 mg of the acyclovir formulation is administered every 4 hours 5 times daily,
(2) 400 mg of the acyclovir formulation is administered 2 times daily,
(3) 200 mg of the acyclovir formulation is administered 3 times daily,
(4) 200 mg of the acyclovir formulation is administered 4 times daily, or
(5) 200 mg of the acyclovir formulation is administered 5 times daily.
8. A dosage unit form comprising:
(A) the pharmaceutical compositions of claim 1; and
(B) (a) an excipient,
(b) a diluent,
(c) a disintegrant,
(d) a lubricant,
(e) a plasticizer,
(f) a colorant,
(g) a dosing vehicle, or
(h) any combination thereof.
9. The dosage unit form of claim 8, wherein the dosage unit form is in the form of a tablet, a capsule, a particle, a powder, a sachet, or a liquid.
10. The dosage unit form of claim 8, wherein the dosing vehicle is a liquid selected from the group consisting of water, aqueous propylene glycol, phosphate buffer, 1,2-propane diol, ethanol, and any combination thereof.
11. A method for administering an effective amount of acyclovir a patient in need of thereof, comprising the step of orally administering the pharmaceutical composition of claim 1.
12. A method of treating a viral infection in a patient in need thereof, comprising the step of administering to the patient an effective amount of the pharmaceutical composition of claim 1.
13. A method of treating a condition or disorder caused by a virus in a patient in need thereof, comprising the step of administering an animal an effective amount of the pharmaceutical composition of claim 1.
14. The method of claim 13, wherein the condition or disorder is caused by a virus selected from the group consisting of herpes simplex 1, herpes simplex 2, varicella zoster virus, cytomegalovirus and Epstein-Ban virus.
15. A method of improving the bioavailability of acyclovir in an animal in need thereof, the method comprising the step of administering a formulation of claim 1.
16. (canceled)